Gilead Sciences Signs $2 Billion Partnership with Arcus Biosciences

Gilead Sciences(NASDAQ:GILD) and Arcus Biosciences(NYSE:RCUS) have signed a 10-year agreement to co-develop and co-commercialize the next-generation cancer therapeutics in Arcus’ pipeline. The agreem… [+1690 chars]Source